Communiqués GSK plc Deutsche Boerse AG

Actions

GS71

GB00BN7SWP63

Produits pharmaceutiques

Marché Fermé - Deutsche Boerse AG Autres places de cotation 21:45:29 31/07/2026			Varia. 5j.	Varia. 1 janv.
22,37 ^EUR	-2,74%		-0,40%	+6,52%

30/07	États-Unis : les laboratoires et distributeurs devront répondre de la mention " efficacité maximale » sur les décongestionnants	RE
30/07	GSK : le directeur de la chaîne d'approvisionnement mondiale cède 38 000 actions	AN

Communiqués

28/07	Glaxo: Q2 Earnings Snapshot	AQ
28/07	GSK : Q2 2026 US dollar translation	PU
28/07	GSK : delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026	PU
23/07	GSK plc - Jideytro approved in the US for previously treated ROS1-positive non-small cell lung cancer	AQ
22/07	GSK : Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer	PU
20/07	GSK : European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds	PU
17/07	GSK : provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)	PU
15/07	What If A Shingles Jab Could Also Protect Your Brain?	AQ
15/07	GSK : completes acquisition of Nuvalent, Inc.	PU
13/07	GSK : Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer	PU
10/07	GSK : licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population	PU
09/07	GSK : Roy Jakobs to join GSK Board as Non-Executive Director	PU
24/06	GSK : announces commencement of tender offer to acquire Nuvalent, Inc.	PU
17/06	Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)	BU
17/06	GSK : Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)	PU
01/06	PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention Choices	BU
28/05	GSK : Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B	PU
26/05	GSK : to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA	PU
18/05	GSK : RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk	PU
11/05	GSK : enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch	PU
07/05	Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults	BU
06/05	GSK : 2026 Remuneration Policy	PU
06/05	GSK : presents latest respiratory research to advance patient care at ATS 2026	PU
30/04	GSK : Q1 2026 results transcript	PU
29/04	The Fifth International Healthcare Week set for next month	AQ